Articles by Daniel Marsh
Sarepta Surges 13% Despite Delay in Elevidys Safety Trial
Sarepta's stock rallied 13% despite a five-month delay in its Elevidys safety study, as investors weigh the new trial site against weak sales and high short interest.
Take-Two Slides 2% as GTA VI Netflix Preview Kicks Off Final Marketing Push
Take-Two (TTWO) shares dropped 2.1% as Rockstar's GTA VI Netflix preview begins the final marketing phase ahead of the November 19 launch. The company maintains its FY2027 bookings guidance of $8.0-$8.2 billion.
10-Year Treasury Yield Hits 4.67% as Markets Await Fed's Jackson Hole Speech
The 10-year Treasury yield climbed to 4.67% on Thursday, buoyed by strong labor data, as investors positioned for Fed Chair Kevin Warsh's Jackson Hole speech on Friday.
Celularity Stock Surges 120% on MuseCell's $300M Manufacturing Deal
Celularity shares more than doubled after MuseCell outlined a potential $300 million manufacturing relationship, though the estimate is non-binding and filings are overdue.
Propanc Biopharma Rockets 151% on Promising PRP Pancreatic Cancer Data
Propanc Biopharma (PPCB) shares jumped 151% after PRP reduced tumor growth by over 90% in pancreatic cancer models, with volume nearly 20 times normal.
Wendy's Shares Tumble 13% as Trian Abandons Take-Private Plans
Wendy's shares dropped 13% after top shareholder Trian Fund Management said it won't pursue a take-private deal, erasing the takeover premium.
Callaway Stock Slips as Retailers Pull Good Good Gear Amid Ad Controversy
Callaway shares dropped 1.3% as major retailers pulled Good Good products after a controversial driver ad. Despite the setback, Q2 golf equipment sales rose 4.5%.
Moderna Drops 5% on $2B Convertible Debt Sale
Moderna shares slid 5% after the company unveiled a $2B convertible notes offering, erasing $3B from its market cap. The financing follows a recent surge in its cancer-vaccine prospects.
Biohaven Shares Slide 7% as Investors Reassess Opakalim Deal Value
Biohaven shares fell 7.1% to $15.75, reversing nearly half of Wednesday's gains from its $400 million opakalim licensing agreement with SK Biopharmaceuticals.
Micron Stock Erases Nvidia Rally Gains as $1,300 Target Draws Focus
Micron (MU) shares gave back most of their Nvidia-driven gains on Thursday, with attention on a $1,300 price target. The memory maker's valuation and earnings outlook remain in focus.
Mercer's Premarket Surge Fades as Canadian Aid Isn't Enough
Mercer International's stock surged 60% premarket on a $14M Canadian aid package, but quickly gave back gains as investors weighed the repayable loan against the company's negative equity and EBITDA.